FOLH1 and prostate cancer: Intraoperative PET/CT specimen imaging has shown promising results in multiple oncological settings, including 18F-FDG avid breast cancer [17], head and neck cancer [18], pancreatic adenocarcinoma [19], as well as SSTR-expressing neuroendocrine tumors and PSMA-expressing prostate cancer [20,21].